AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026)

AtaiBeckley's (ATAI) quarterly Cash from Investing Activities came in at -$21.7 million in Q1 2026, down 96.6% year-on-year from -$636.0 million in Q1 2025, and down 96.6% quarter-over-quarter from -$11.0 million in Q1 2025.

AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026) Analysis & Trends

AtaiBeckley (ATAI) has 6 years of Cash from Investing Activities data on file, last reported at -$67.6 million in Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 371.95% year-over-year to -$67.6 million; the trailing twelve-month figure through Sep 2025 stood at -$62.2 million (down 220.15% YoY), and the FY2024 full-year result was $59.2 million, up 211.03% from the prior year.
  • Cash from Investing Activities eased to -$21.7 million in Q1 2026 per ATAI's latest filing, from -$11.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$11.0 million in Q1 2025 and bottomed at -$21.7 million in Q1 2026.
  • A 5-year average of -$12.2 million and a median of -$823000.0 in 2023 frame the typical range for Cash from Investing Activities.
  • Peak annual rise in Cash from Investing Activities reached 10857.33% in 2022, while the deepest fall reached 5670.92% in 2022.
  • Tracing ATAI's Cash from Investing Activities over 5 years: stood at -$48.6 million in 2021, then jumped by 264.6% to $80.1 million in 2022, then tumbled by 101.03% to -$823000.0 in 2023, then surged by 897.08% to $6.6 million in 2024, then sank by 1129.77% to -$67.6 million in 2025.
  • Business Quant data shows ATAI's Cash from Investing Activities at -$67.6 million in Q3 2025, $9.8 million in Q2 2025, and -$11.0 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 AtaiBeckley 1.56 Bn 1.56 Bn - -67.55 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -21.65 Mn
Mar 31, 2026 -21.65 Mn
Sep 30, 2025 -67.55 Mn
Sep 30, 2025 -67.55 Mn
Jun 30, 2025 9.78 Mn
Jun 30, 2025 9.78 Mn
Mar 31, 2025 -11.01 Mn
Mar 31, 2025 -11.01 Mn
Mar 31, 2025 -11.01 Mn
Mar 31, 2025 -11.01 Mn
Dec 31, 2024 6.56 Mn
Dec 31, 2024 6.56 Mn
Sep 30, 2024 24.84 Mn
Sep 30, 2024 24.84 Mn
Jun 30, 2024 16.30 Mn
Jun 30, 2024 16.30 Mn
Mar 31, 2024 11.47 Mn
Mar 31, 2024 11.47 Mn
Dec 31, 2023 -823,000.00
Dec 31, 2023 -823,000.00